ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
US Tech 100
18,062.00
-0.10%
Dow Jones
40,003.59
0.34%
Brent Oil
83.76
0.00%
Bitcoin
67,390.92
0.46%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. UroGen Pharma Ltd (URGN) Quote

UroGen Pharma Ltd

UroGen Pharma Ltd (URGN)

NASDAQ
13.22
0.01
(0.08%)
Closed May 18 4:00PM
Delayed by 15 minutes
13.22
0.00
(0.00%)
After Hours: 4:00PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
13.22
Bid
13.00
Ask
14.99
Volume
232,110
13.04 Day's Range 13.345
8.69 52 Week Range 24.13
Market Cap
452.8M
Previous Close
13.21
Open
13.22
Last Trade
99
@
13.5
Last Trade Time
Financial Volume
$ 3,052,840
VWAP
13.1526
Average Volume (3m)
333,918
Shares Outstanding
34,122,087
Dividend Yield
-
PE Ratio
-4.43
Earnings Per Share (EPS)
-3
Revenue
82.71M
Net Profit
-102.24M

About UroGen Pharma Ltd

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.urogen.com
Headquarters
Ra'anana, Center, Isr
Founded
1970
UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was $13.21. Over the last year, UroGen Pharma shares have traded in a share price range of $ 8.69 to $ 24.13.

UroGen Pharma currently has 34,122,087 shares outstanding. The market capitalization of UroGen Pharma is $452.80 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.43.

URGN Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 13 2024
Edgar (US Regulatory)

UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights

12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024 ENVISION data expected to support completion of UGN-102...

May 13 2024
Business Wire

UroGen Pharma to Participate at Upcoming Investor Conferences

– Citizens JMP Life Sciences Conference – – H.C. Wainwright 2nd Annual BioConnect Conference – UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

May 07 2024
Business Wire

New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy

There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location RFS Was 100% in Patients who Received Maintenance...

May 05 2024
Business Wire

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and...

May 04 2024
Business Wire

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing...

May 04 2024
Business Wire

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

Conference Call and Webcast Scheduled for Monday, May 13, 2024, at 10:00AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions...

May 03 2024
Business Wire

UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers

Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term...

April 17 2024
Business Wire

UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mitomycin dosage strength that may considerably shorten...

April 15 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.251.9275250578312.9714.0510.600144641913.2066604CS
4-0.84-5.9743954480814.0614.8910.600128437913.61692553CS
12-4.57-25.68858909517.7918.719410.600133391815.02297258CS
261.0258.4050840508412.19519.8710.600132429815.32038131CS
521.4712.510638297911.7524.138.6937820916.16550899CS
156-2.03-13.311475409815.2524.134.8520906713.99178281CS
260-25.34-65.715767634938.5639.884.8520155418.32037371CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DUOFangDD Network Group Ltd
$ 1.65
(313.74%)
104.68M
FLJFLJ Group Limited
$ 1.54
(220.90%)
57.28M
JFBRJeffs Brands Ltd
$ 0.6276
(102.45%)
37.97M
IPWiPower Inc
$ 2.89
(97.95%)
11.05M
CETXCemtrex Inc
$ 0.4851
(48.58%)
21.23M
BSFCBlue Star Foods Corporation
$ 0.0757
(-45.26%)
60.09M
SINTSiNtx Technologies Inc
$ 0.084602
(-39.57%)
156.35M
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
HSCSHeart Test Laboratories Inc
$ 7.00
(-38.11%)
348.9k
AMPGAmplitech Group Inc
$ 1.46
(-32.09%)
613.31k
CRKNCrown Electrokinetics Corporation
$ 0.171
(-28.75%)
1.74B
FFIEFaraday Future Intelligent Electric Inc
$ 1.0189
(-38.25%)
1.31B
GWAVGreenwave Technology Solutions Inc
$ 0.1541
(4.05%)
1.16B
AKANAkanda Corporation
$ 0.1726
(30.26%)
566.51M
PEGYPineapple Energy Inc
$ 0.1053
(-28.85%)
219.25M

Discussion

View Full Feed
SEV123 SEV123 4 minutes ago
The 84-Year-Old Man Who Saved Nvidia
It’s a $2 trillion company today. It wouldn’t exist without someone known as Irimajiri-san.

Before it was one of the world’s most valuable companies, Nvidia NVDA -1.99%decrease; red down pointing triangle

was a company on the
NVDA
floridaboy floridaboy 5 minutes ago
Need sustained buying pressure
SAPX
Shoreline fever Shoreline fever 6 minutes ago
Enthalpy,
May i ask why you would believe whatever it is Wolfgang might have told you? Falak has been in charge for roughly 13 years and where are we ?
What has he predicted that would give him your trust?
Thanks
PSPW
TRUISM TRUISM 7 minutes ago
At some point, they'll decide to produce actual prototypes; just to be certain all quality parameters are met.

I believe this will come before going "full steam ahead" with the pursuit of metric ton production.



Now we just need them to hit their metric
KBLB
MightyX MightyX 9 minutes ago
When I choose to expose or not is-on me.
TPTW
MightyX MightyX 9 minutes ago
I don’t buy subpenny…my narrative is against-the-traders that do for dilution accumulation purposes only.
TPTW
Seminole Red Seminole Red 12 minutes ago
LOUISVILLE, Ky. — John Daly withdrew on Friday morning ahead of the second round of the 106th playing of the PGA Championship.

Daly, 58, the winner of the 1991 PGA Championship, cited a thumb injury. He made his 30th career start at the PGA on Thursday and shot 11-over 82 at Valhalla
Freddie bagholder Freddie bagholder 16 minutes ago
THIS IS TRUMP TRADE. Begins June, 2024.
FNMA
d0lphint0m d0lphint0m 17 minutes ago
I take it as a bullish sign for otc that crkn and ffie are exploding out of nowhere.
GDVM
The ELTP King The ELTP King 18 minutes ago
HOLY SH*T you're PHUCKIN' good!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Are you phuckin' kidding me right now!!!!!!!!!???????

February 16 - GDUFA date
***3-month minor amendment review***
May 16 - APPROVED

April 4, 2024:

A minor a
ELTP
The ELTP King The ELTP King 18 minutes ago
WeeZuhl is STUNNED in disbelief.

WeeZuhl: "The methotrexate bioequivalence study in India was never started."

The King: "Methotrexate is the name of the undisclosed antimetabolite. It was supposed to be approved in February but received a CRL. The BE study date
CRL
The ELTP King The ELTP King 18 minutes ago
The King does it again!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Holy SH*T you're phuckin' GOOD!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

APRIL 7, 2024: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174193094

********** NEW **********
ELTP
highlandernew highlandernew 19 minutes ago
🔴🔴AMC FULL CAT compliance coming-to NOT "in-good-faith" Liquidity Fairies?:

***
*** The NOT "in good faith" BONA FIDE is ending? ***
***

https://inve
AMC
TrendTrade2016 TrendTrade2016 21 minutes ago
OCG.V...WATCH THIS SILVER PLAY FLY INTO THE BOOM!
OCG
peafunke peafunke 21 minutes ago
Interesting how you disappear when the big dump of shares happened a few days ago. You claim others were ‘waiting’ and keeping the sp low but in fact it was you who has disappeared several times when those shares seem to suddenly flood the market. I’m just sayin…. It could actually be you doing th
TPTW
Genz2 Genz2 22 minutes ago
https://www.bleepingcomputer.com/news/microsoft/microsoft-will-start-enforcing-azure-multi-factor-authentication-MFA-in-july-2024/amp/

Microsoft doesn’t even mention the use of the TPM as a factor of authentication!! And if it does use the TPM, Wave can still manage all the TPMs and
biosectinvestor biosectinvestor 23 minutes ago
Hyperopia, I agree pretty much straight down the line with you. I am actually quite certain that poly iclc is not used as a “maturation agent” and have debated that previously with ATL. Recently ATL conceded it’s not true. There is no indication that is true or even that it makes sense, IMHO. It was
NWBO
walterc walterc 25 minutes ago
if we can continue this progress and apply . a normal P/E ratio IBC is seriously undervalued.
IAALF
MitchDB MitchDB 27 minutes ago
I’m worried we see 0.0004 or 0.0003 next week
This company is such a failure
EPAZ
gdog gdog 27 minutes ago
yes boc it was proven that Samsung did in fact Breach the contracr with NLST.
NLST
pepeoil pepeoil 28 minutes ago
Educate me, show me a link bruh? Or did you hear that at the bar? Bwahaaaa
ASRE
gatorhistory gatorhistory 29 minutes ago
Lol we need all the mental help we can get here at this point.
NICH
bratrat bratrat 29 minutes ago
From Provectus's most recent substack posting.

https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb6167475-8e2a-4bdd-bf86-311a5973790f_2246x1270.png

this seems so astonishing
PVCT

Your Recent History

NASDAQ
URGN
UroGen Pharma
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved